Related Articles
Efficacy of cetuximab‑based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta‑analysis
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival
Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver‑only and lung‑only metastases
EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
Effects of BRAF V600E and NRAS mutational status on the progression‑free survival and clinicopathological characteristics of patients with melanoma